Physiologic modeling of cyclosporin kinetics in rat and man

  • Alberto Bernareggi
  • Malcolm Rowland


A physiologic pharmacokinetic model of cyclosporin has been developed in the rat aimed at predicting the time course of drug concentrations in blood, organs, and tissues. The model assumes that tissue distribution is perfusion-rate limited and that each tissue acts as a well-stirred compartment. The unbound equilibrium distribution ratios as well as the values of the fraction unbound and the distributon isotherm of cyclosporin between erythrocytes and plasma are included in the rate equations describing the time course of the drug concentration in each tissue. Parameter values for the rat were obtained experimentally from a continuous infusion study, in which 2.7 and I3.9mg/kg per day doses of cyclosporin were administered subcutaneously to each of two groups of rats by osmotic pumps for 6 days. Steady-state cyclosporin concentrations in blood, CSF, and 18 different organs and tissues, were determined by a monoclonal antibody RIA. Differences in values of the unbound equilibrium distribution ratios in some tissues and unbound clearance indicated that both the processes of distribution and elimination may have elements of nonlinearity over the range of dosing rales tested. The model was evaluated in the rat with a kinetic experiment in which a 6-mg/kg dose of cyclosporin was infused intravenously over 15 min, with measurements of blood concentrations until 56 hr. Good agreement was obtained for the volume of distribution at steady state (blood), V xs between the perfusion model and that calculated from the kinetic experiment. Also, the model prediction of the blood concentration temporal profile agreed closely with that observed except in the early moments, when distribution out of blood occurred considerably slower than predicted. On scaling the model up to humans, good agreement was found between the predicted plasma concentration-time profile and V ss ,and experimental data from the literature. Both rat and human data suggest that partition into adipose tissue plays an important role in the pharmacokinetics of cyclosporin.

Key words

cyclosporin physiologic pharmacokinetic model intravenous infusion rat man osmotic pumps distribution study RIA organs blood content interspecies scaling 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. F. Borel, C. Freurer, H. U. Gubler, and H. Staheiin. Biological effects of cyclosporin A: a new antilymphocytic agent.Agents Actions 6:468–475 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    A. D. Hess and P. M. Colombani. Mechanism of action: In vitro studies. InCiclosporin. Progress in Allergy Vol. 38, S. Karger, Basel, 1986, pp. 198–221.Google Scholar
  3. 3.
    C. J. Green. Experimental transplantation. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 123–158.Google Scholar
  4. 4.
    T. Beveridge. Clinical transplantation—Overview. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 269–292.Google Scholar
  5. 5.
    R. B. Nussenblatt, H. C. Gunn, B. Ryffel, and J. F. Borel. Experimental autoimmunity. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 159–180.Google Scholar
  6. 6.
    B. V. Graffenried. Ciclosporin in autoimmune diseases. InCiclosporin. Progress in Allergy, Vol. 38, S. Karger, Basel, 1986, pp. 432–435.Google Scholar
  7. 7.
    S. K. Gupta, B. Legg, L. R. Solomon, R. W. G. Johnson, and M. Rowland. Pharmacokinetics of cyclosporin: Influence of rate of constant intravenous infusion in renal transplant patients.Br. J. Clin. Pharmacol. 24:519–526 (1987).PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    F. Follath, M. Wenk, S. Vozeh, G. Thiel, F. Brunner, R. Loertscher, M. Lemaire, K. Nussbaumer, W. Niederberger, and A. J. Wood. Intravenous cyclosporin kinetics in renal failure.Clin. Pharmacol. Ther. 34:638–643 (1983).PubMedCrossRefGoogle Scholar
  9. 9.
    O. Wagner, E. Schreier, F. Heitz, and G. Maurer. Tissue distribution, disposition, and metabolism of cyclosporin in rats.Drug Metab. Dispos. 15:377–383 (1987).PubMedGoogle Scholar
  10. 10.
    K. Atkinson, J. Boland, K. Britton, and J. Biggs. Blood and tissue distribution of cyclosporin in humans and mice.Transpl. Proc. 15:2430–2449 (1983).Google Scholar
  11. 11.
    M. Ried, S. Gibbons, D. Kwok, C. T. Van Buren, S. Flechner, and B. D. Kahan. Cyclosporin levels in human tissues of patients treated for one week to one year.Transpl. Proc. 15:2434–2437 (1983).Google Scholar
  12. 12.
    G. Maurer, H. R. Loosly, E. Schreier, and B. Keller. Disposition of cyclosporin in several animal species and man. Structural elucidation of its metabolites.Drug Metab. Dispos. 12:120–126 (1984).PubMedGoogle Scholar
  13. 13.
    A. J. Wood, G. Maurer, W. Niederberger, and T. Beveridge. Cyclosporin: Pharmacokinetics, metabolism, and drug interactions.Transpl. Proc. 15:2409–2412 (1983).Google Scholar
  14. 14.
    P. E. Ball, H. Munzer, H. P. Keller, E. Abisch, and J. Rosenthaler, Specific [3H]radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in blood.Clin. Chem. 34:257–260 (1988).PubMedGoogle Scholar
  15. 15.
    B. Legg and M. Rowland. Cyclosporin A: Measurement of fraction unbound in plasma.J. Pharm. Pharmacol. 39:599–603 (1987).PubMedCrossRefGoogle Scholar
  16. 16.
    D. H. Jung, H. G. Biggs, and W. R. Moorehead. Colorimetry of serum cholesterol with use of ferric acetate/uranyl acetate and ferrous sulfate/sulphuric acid reagents.Clin. Chem. 21:1526–1530 (1975).PubMedGoogle Scholar
  17. 17.
    M. Gibaldi and D. Perrier. (eds).Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982.Google Scholar
  18. 18.
    K. S. Pang and M. Rowland. Hepatic clearance of drugs, I. Theoretical consideration of a “well stirred” and a “parallel tube” model. Influence of hepatic blood, plasma and blood binding and hepatocellular enzyme activity on hepatic drug clearance.J. Pharmacokin. Biopharm. 5:625–653 (1977).CrossRefGoogle Scholar
  19. 19.
    W. Niederberger, M. Lemaire, G. Maurer, K. Nussbaumer, and O. Wagner. Distribution and binding of cyclosporin in blood and tissues.Transpl. Proc. 15:2419–2421 (1983).Google Scholar
  20. 20.
    B. Legg and M. Rowland. Cyclosporin: Erythrocyte binding and an examination of its use to estimate unbound concentration.Theor. Drug Monit. 10:16–19 (1988).CrossRefGoogle Scholar
  21. 21.
    H. H. Donaldson.The rat. Data and Reference Tables, 2nd ed., Memoirs of the Wistar Institute of Anatomy and Biology, No. 6, Philadelphia, 1924, pp. 183–189.Google Scholar
  22. 22.
    Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano. Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.J. Pharmacokin. Biopharm. 11:577–593 (1983).CrossRefGoogle Scholar
  23. 23.
    R. J. Lutz, R. L. Dedrick, H. B. Matthews, T. E. Eling, and M. W. Andersen. A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat.Drug Metab. Dispos. 5:386–396 (1977).PubMedGoogle Scholar
  24. 24.
    J. Idvall, K. F. Aronsen, and P. Stenberg. Tissue perfusion and distribution of cardiac output during ketamine anaesthesia in normovolemic rats.Acta Anaesth. Scand. 24:257–263 (1980).PubMedCrossRefGoogle Scholar
  25. 25.
    Y. Sasaki and H. N. Wagner Jr. Measurement of the distribution of cardiac output in unanesthetized rats.J. Appl. Physiol. 30:879–884 (1971).PubMedGoogle Scholar
  26. 26.
    A. Schoutens, P. Bergmann, and M. Verhas. Bone blood flow measured by85Sr microspheres and bone seeker clearances in the rat.Am. J. Physiol. 236:H1-H6 (1979).PubMedGoogle Scholar
  27. 27.
    H. J. Baker, (ed.).The Laboratory Rat Vol. I. In American College of Laboratory Animal Medicine Series, Academic Press, New York, 1979, p. 87.Google Scholar
  28. 28.
    J. P. Schaeffer. (ed.).Morris' Human Anatomy, 11th ed. Blakiston, London, 1953.Google Scholar
  29. 29.
    V. Fiserova-Bergerova. (ed.).Modelling of Inhalation Exposure to Vapors, Vol. I, CRC Press, Boca Raton, FL, 1983, p. 88.Google Scholar
  30. 30.
    A. C. Guyton. (ed.).Textbook of Medical Physiology, W. B. Saunders, Philadelphia, 1966, p. 279.Google Scholar
  31. 31.
    R. L. Dedrick, D. D. Forrester, and D. H. W. Ho. In vitro-in vivo correlation of drug metabolism. Deamination of 1-beta-D-arabinofuranosylcytosine.Biochem. Pharmacol. 21:1–16 (1972).PubMedCrossRefGoogle Scholar
  32. 32.
    G. Bell, J. N. Davidson, and H. Scarborough, (ed.).Textbook of Physiology and Biochemistry, 6th ed., Livingstone, London, 1965, p. 512.Google Scholar
  33. 33.
    M. Rowland and T. N. Tozer. (eds.).Clinical Pharmacokinetics: Concepts and Applications, 2nd ed., Lea & Febiger, Philadelphia, 1989, chap. 19.Google Scholar
  34. 34.
    B. Legg, S. K. Gupta, and M. Rowland. A model to account for the variation in cyclosporin binding to plasma lipids in transplant patients.Ther. Drug Monit. 10:20–27 (1988).PubMedCrossRefGoogle Scholar
  35. 35.
    R. J. Ptachcinski, R. Venkataramanan, and G. J. Burckart. Clinical pharmacokinetics of cyclosporin.Clin. Pharmacokin. 11:107–132 (1986).CrossRefGoogle Scholar
  36. 36.
    J. K. Fazakorley and H. E. Webb. Cyclosporin, blood brain barrier, and multiple sclerosis.Lancet 2:889–890 (1985).CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1991

Authors and Affiliations

  • Alberto Bernareggi
    • 1
  • Malcolm Rowland
    • 1
  1. 1.Department of PharmacyUniversity of ManchesterManchesterEngland

Personalised recommendations